Paper28539619
Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab.
Hansen TF and 4 others. Sci Rep, 2017. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. Papers, record 28539619. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28539619
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Bevacizumab | Major topic |
| Biomarkers, Tumor | Major topic |
| Colorectal Neoplasms | Major topic |
| Endothelial Growth Factors | Major topic |
| Polymorphism, Single Nucleotide | Major topic |
| Adult | |
| Aged | |
| Calcium-Binding Proteins | |
| Capecitabine | |
| EGF Family of Proteins | |
| Female | |
| Humans | |
| Lymphatic Metastasis | |
| Male | |
| Middle Aged | |
| Oxaliplatin | |
| Prognosis | |
| Prospective Studies | |
| Survival Analysis |
Source PubMed
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21407216 | Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. | Br J Cancer | 2011 | https://conductscience.org/library/papers/21407216 | PubMed |
| 2 | 21433001 | Biospecimen reporting for improved study quality (BRISQ). | Cancer Cytopathol | 2011 | https://conductscience.org/library/papers/21433001 | PubMed |
| 3 | 15162510 | Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells. | Dev Dyn | 2004 | https://conductscience.org/library/papers/15162510 | PubMed |
| 4 | 23945239 | Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. | J Clin Invest | 2013 | https://conductscience.org/library/papers/23945239 | PubMed |
| 5 | 25113767 | Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials. | J Clin Oncol | 2014 | https://conductscience.org/library/papers/25113767 | PubMed |
| 6 | 23386126 | EGFL7 ligates αvβ3 integrin to enhance vessel formation. | Blood | 2013 | https://conductscience.org/library/papers/23386126 | PubMed |
| 7 | 16106245 | REporting recommendations for tumour MARKer prognostic studies (REMARK). | Br J Cancer | 2005 | https://conductscience.org/library/papers/16106245 | PubMed |
| 8 | 17934064 | Epidermal growth factor-like domain 7 protects endothelial cells from hyperoxia-induced cell death. | Am J Physiol Lung Cell Mol Physiol | 2008 | https://conductscience.org/library/papers/17934064 | PubMed |
| 9 | 14592969 | VE-statin, an endothelial repressor of smooth muscle cell migration. | EMBO J | 2003 | https://conductscience.org/library/papers/14592969 | PubMed |
| 10 | 22139032 | The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. | Int J Colorectal Dis | 2012 | https://conductscience.org/library/papers/22139032 | PubMed |
| 11 | 17626061 | EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. | Development | 2007 | https://conductscience.org/library/papers/17626061 | PubMed |
| 12 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 13 | 25584492 | Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. | Br J Cancer | 2015 | https://conductscience.org/library/papers/25584492 | PubMed |
| 14 | 25308363 | Prognostic significance of epidermal growth factor-like domain 7 in pancreatic cancer. | Hepatobiliary Pancreat Dis Int | 2014 | https://conductscience.org/library/papers/25308363 | PubMed |
| 15 | 15085134 | The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. | Nature | 2004 | https://conductscience.org/library/papers/15085134 | PubMed |
| 16 | 23669226 | Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23669226 | PubMed |
| 17 | 23922111 | MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. | Br J Cancer | 2013 | https://conductscience.org/library/papers/23922111 | PubMed |
| 18 | 15972971 | EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. | Am J Pathol | 2005 | https://conductscience.org/library/papers/15972971 | PubMed |
| 19 | 25140000 | Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer. | Mol Cancer Ther | 2014 | https://conductscience.org/library/papers/25140000 | PubMed |
| 20 | 23558933 | The expression of Egfl7 in human normal tissues and epithelial tumors. | Int J Biol Markers | 2013 | https://conductscience.org/library/papers/23558933 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41859310 | The Association of EGFL7 Polymorphism and Expression with Cervical Cancer Susceptibility and Pathogenesis. | Int J Gen Med | 2026 | https://conductscience.org/library/papers/41859310 | PubMed |
| 38790260 | Elucidating Cancer Subtypes by Using the Relationship between DNA Methylation and Gene Expression. | Genes (Basel) | 2024 | https://conductscience.org/library/papers/38790260 | PubMed |
| 37957249 | Low EGFL7 expression is associated with high lymph node spread and invasion of lymphatic vessels in colorectal cancer. | Sci Rep | 2023 | https://conductscience.org/library/papers/37957249 | PubMed |
| 35698739 | EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome. | J Pathol Transl Med | 2022 | https://conductscience.org/library/papers/35698739 | PubMed |
| 35494025 | The Polymorphism and Expression of EGFL7 and miR-126 Are Associated With NSCLC Susceptibility. | Front Oncol | 2022 | https://conductscience.org/library/papers/35494025 | PubMed |
| 34217251 | Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma. | BMC Cancer | 2021 | https://conductscience.org/library/papers/34217251 | PubMed |
| 34017420 | Epidermal growth factor-like domain 7 regulates breast cancer cell proliferation and vascular endothelial growth factor expression via the p38MAPK signaling pathway. | Am J Transl Res | 2021 | https://conductscience.org/library/papers/34017420 | PubMed |
| 33917022 | Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33917022 | PubMed |
| 33635474 | EGFL7 as a novel therapeutic candidate regulates cell invasion and anoikis in colorectal cancer through PI3K/AKT signaling pathway. | Int J Clin Oncol | 2021 | https://conductscience.org/library/papers/33635474 | PubMed |
| 31824558 | The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer. | Front Genet | 2019 | https://conductscience.org/library/papers/31824558 | PubMed |
| 31245291 | microRNA-126 Is a Tumor Suppressor of Granulosa Cell Tumor Mediated by Its Host Gene EGFL7. | Front Oncol | 2019 | https://conductscience.org/library/papers/31245291 | PubMed |
| 30561001 | Genetic variants in SLC22A3 contribute to the susceptibility to colorectal cancer. | Int J Cancer | 2019 | https://conductscience.org/library/papers/30561001 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| CIRSR | 9541 | PubTator's text mining | https://conductscience.org/library/genes/9541 | NCBI Gene |
| EGFL7 | 51162 | PubTator's text mining | https://conductscience.org/library/genes/51162 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| MIR126 | 406913 | PubTator's text mining | https://conductscience.org/library/genes/406913 | NCBI Gene |
| NRAS | 4893 | PubTator's text mining | https://conductscience.org/library/genes/4893 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
| ZHX2 | 22882 | PubTator's text mining | https://conductscience.org/library/genes/22882 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28539619
GET https://conductscience.org/api/papers/v1/28539619/references?page=2